Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4
- PMID: 32282020
- PMCID: PMC7154955
- DOI: 10.1001/jamaneurol.2020.0414
Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4
Abstract
Importance: Identification of genetic factors that interact with the apolipoprotein e4 (APOE4) allele to reduce risk for Alzheimer disease (AD) would accelerate the search for new AD drug targets. Klotho-VS heterozygosity (KL-VSHET+ status) protects against aging-associated phenotypes and cognitive decline, but whether it protects individuals who carry APOE4 from AD remains unclear.
Objectives: To determine if KL-VSHET+ status is associated with reduced AD risk and β-amyloid (Aβ) pathology in individuals who carry APOE4.
Design, setting, and participants: This study combined 25 independent case-control, family-based, and longitudinal AD cohorts that recruited referred and volunteer participants and made data available through public repositories. Analyses were stratified by APOE4 status. Three cohorts were used to evaluate conversion risk, 1 provided longitudinal measures of Aβ CSF and PET, and 3 provided cross-sectional measures of Aβ CSF. Genetic data were available from high-density single-nucleotide variant microarrays. All data were collected between September 2015 and September 2019 and analyzed between April 2019 and December 2019.
Main outcomes and measures: The risk of AD was evaluated through logistic regression analyses under a case-control design. The risk of conversion to mild cognitive impairment (MCI) or AD was evaluated through competing risks regression. Associations with Aβ, measured from cerebrospinal fluid (CSF) or brain positron emission tomography (PET), were evaluated using linear regression and mixed-effects modeling.
Results: Of 36 530 eligible participants, 13 782 were excluded for analysis exclusion criteria or refusal to participate. Participants were men and women aged 60 years and older who were non-Hispanic and of Northwestern European ancestry and had been diagnosed as being cognitively normal or having MCI or AD. The sample included 20 928 participants in case-control studies, 3008 in conversion studies, 556 in Aβ CSF regression analyses, and 251 in PET regression analyses. The genotype KL-VSHET+ was associated with reduced risk for AD in individuals carrying APOE4 who were 60 years or older (odds ratio, 0.75 [95% CI, 0.67-0.84]; P = 7.4 × 10-7), and this was more prominent at ages 60 to 80 years (odds ratio, 0.69 [95% CI, 0.61-0.79]; P = 3.6 × 10-8). Additionally, control participants carrying APOE4 with KL-VS heterozygosity were at reduced risk of converting to MCI or AD (hazard ratio, 0.64 [95% CI, 0.44-0.94]; P = .02). Finally, in control participants who carried APOE4 and were aged 60 to 80 years, KL-VS heterozygosity was associated with higher Aβ in CSF (β, 0.06 [95% CI, 0.01-0.10]; P = .03) and lower Aβ on PET scans (β, -0.04 [95% CI, -0.07 to -0.00]; P = .04).
Conclusions and relevance: The genotype KL-VSHET+ is associated with reduced AD risk and Aβ burden in individuals who are aged 60 to 80 years, cognitively normal, and carrying APOE4. Molecular pathways associated with KL merit exploration for novel AD drug targets. The KL-VS genotype should be considered in conjunction with the APOE genotype to refine AD prediction models used in clinical trial enrichment and personalized genetic counseling.
Conflict of interest statement
Figures
Comment in
-
Longevity Gene KLOTHO and Alzheimer Disease-A Better Fate for Individuals Who Carry APOE ε4.JAMA Neurol. 2020 Jul 1;77(7):798-800. doi: 10.1001/jamaneurol.2020.0112. JAMA Neurol. 2020. PMID: 32282012 No abstract available.
Similar articles
-
Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden.JAMA Netw Open. 2022 Nov 1;5(11):e2243232. doi: 10.1001/jamanetworkopen.2022.43232. JAMA Netw Open. 2022. PMID: 36413367 Free PMC article.
-
KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD.Neurology. 2019 Apr 16;92(16):e1878-e1889. doi: 10.1212/WNL.0000000000007323. Epub 2019 Mar 13. Neurology. 2019. PMID: 30867273 Free PMC article.
-
Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk.PLoS One. 2022 May 26;17(5):e0267298. doi: 10.1371/journal.pone.0267298. eCollection 2022. PLoS One. 2022. PMID: 35617280 Free PMC article.
-
Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.Neuropsychol Rev. 2014 Sep;24(3):290-9. doi: 10.1007/s11065-014-9263-8. Epub 2014 Aug 22. Neuropsychol Rev. 2014. PMID: 25146994 Review.
-
Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.Rev Neurol (Paris). 2013 Oct;169(10):729-36. doi: 10.1016/j.neurol.2013.07.025. Epub 2013 Sep 6. Rev Neurol (Paris). 2013. PMID: 24016463 Review.
Cited by
-
The concept of resilience to Alzheimer's Disease: current definitions and cellular and molecular mechanisms.Mol Neurodegener. 2024 Apr 8;19(1):33. doi: 10.1186/s13024-024-00719-7. Mol Neurodegener. 2024. PMID: 38589893 Free PMC article. Review.
-
Organ-specific aging in the plasma proteome predicts disease.Trends Mol Med. 2024 May;30(5):423-424. doi: 10.1016/j.molmed.2024.01.005. Epub 2024 Jan 31. Trends Mol Med. 2024. PMID: 38302317
-
Deep neural networks with controlled variable selection for the identification of putative causal genetic variants.Nat Mach Intell. 2022 Sep;4(9):761-771. doi: 10.1038/s42256-022-00525-0. Epub 2022 Sep 15. Nat Mach Intell. 2022. PMID: 37859729 Free PMC article.
-
Targeting neuroendocrine abnormalities in Parkinson's disease with exercise.Front Neurosci. 2023 Sep 8;17:1228444. doi: 10.3389/fnins.2023.1228444. eCollection 2023. Front Neurosci. 2023. PMID: 37746149 Free PMC article.
-
Lower mortality risk in APOE4 carriers with normal cognitive ageing.Sci Rep. 2023 Sep 12;13(1):15089. doi: 10.1038/s41598-023-41078-5. Sci Rep. 2023. PMID: 37699966 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous